Identification of Broad-Spectrum MMP Inhibitors by Virtual Screening

Matrix metalloproteinases (MMPs) are the family of proteases that are mainly responsible for degrading extracellular matrix (ECM) components. In the skin, the overexpression of MMPs as a result of ultraviolet radiation triggers an imbalance in the ECM turnover in a process called photoaging, which ultimately results in skin wrinkling and premature skin ageing. Therefore, the inhibition of different enzymes of the MMP family at a topical level could have positive implications for photoaging. Considering that the MMP catalytic region is mostly conserved across different enzymes of the MMP family, in this study we aimed to design a virtual screening (VS) workflow to identify broad-spectrum MMP inhibitors that can be used to delay the development of photoaging. Our in silico approach was validated in vitro with 20 VS hits from the Specs library that were not only structurally different from one another but also from known MMP inhibitors. In this bioactivity assay, 18 of the 20 compounds inhibit at least one of the assayed MMPs at 100 μM (with 5 of them showing around 50% inhibition in all the tested MMPs at this concentration). Finally, this VS was used to identify natural products that have the potential to act as broad-spectrum MMP inhibitors and be used as a treatment for photoaging.

[1]  M. Neagu,et al.  Current Perspectives on the Role of Matrix Metalloproteinases in the Pathogenesis of Basal Cell Carcinoma , 2021, Biomolecules.

[2]  V. Kähäri,et al.  Matrix metalloproteinases in keratinocyte carcinomas , 2020, Experimental dermatology.

[3]  Adrià Cereto-Massagué,et al.  The Light and Dark Sides of Virtual Screening: What Is There to Know? , 2019, International journal of molecular sciences.

[4]  R. Maizels,et al.  Demonstration of the Anthelmintic Potency of Marimastat in the Heligmosomoides polygyrus Rodent Model , 2018, Journal of Parasitology.

[5]  J. Min,et al.  New insights on the MMP-13 regulatory network in the pathogenesis of early osteoarthritis , 2017, Arthritis Research & Therapy.

[6]  Leland McInnes,et al.  hdbscan: Hierarchical density based clustering , 2017, J. Open Source Softw..

[7]  George Papadatos,et al.  The ChEMBL database in 2017 , 2016, Nucleic Acids Res..

[8]  J. Meephansan,et al.  Role of Matrix Metalloproteinases in Photoaging and Photocarcinogenesis , 2016, International journal of molecular sciences.

[9]  M. Walkinshaw,et al.  Identification and activity of inhibitors of the essential nematode-specific metalloprotease DPY-31 , 2015, Bioorganic & medicinal chemistry letters.

[10]  T. A. Gureeva,et al.  [Matrix metalloproteinases and their endogenous regulators in squamous cervical carcinoma (review of the own data)]. , 2015, Biomeditsinskaia khimiia.

[11]  John J. Irwin,et al.  ZINC 15 – Ligand Discovery for Everyone , 2015, J. Chem. Inf. Model..

[12]  Ashleigh Pulkoski-Gross.  Historical perspective of matrix metalloproteases. , 2015, Frontiers in bioscience.

[13]  Jian Cao,et al.  MMP Inhibitors: Past, present and future. , 2015, Frontiers in bioscience.

[14]  G. Imokawa,et al.  Biological Mechanisms Underlying the Ultraviolet Radiation-Induced Formation of Skin Wrinkling and Sagging II: Over-Expression of Neprilysin Plays an Essential Role , 2015, International journal of molecular sciences.

[15]  M. Slomka,et al.  Role of MMP-2 and MMP-9 and their natural inhibitors in liver fibrosis, chronic pancreatitis and non-specific inflammatory bowel diseases. , 2014, Hepatobiliary & pancreatic diseases international : HBPD INT.

[16]  R. Vandenbroucke,et al.  Is there new hope for therapeutic matrix metalloproteinase inhibition? , 2014, Nature Reviews Drug Discovery.

[17]  Benjamin Fabre,et al.  Targeting matrix metalloproteinases: exploring the dynamics of the s1' pocket in the design of selective, small molecule inhibitors. , 2014, Journal of medicinal chemistry.

[18]  Adrià Cereto-Massagué,et al.  The good, the bad and the dubious: VHELIBS, a validation helper for ligands and binding sites , 2013, Journal of Cheminformatics.

[19]  Armando Rossello,et al.  Crystallization of bi-functional ligand protein complexes. , 2013, Journal of structural biology.

[20]  Claudio Luchinat,et al.  Molecular determinants of a selective matrix metalloprotease-12 inhibitor: insights from crystallography and thermodynamic studies. , 2013, Journal of medicinal chemistry.

[21]  Adrià Cereto-Massagué,et al.  DecoyFinder: an easy-to-use python GUI application for building target-specific decoy sets , 2012, Bioinform..

[22]  Gaël Varoquaux,et al.  Scikit-learn: Machine Learning in Python , 2011, J. Mach. Learn. Res..

[23]  Ying Yu,et al.  Orally active MMP-1 sparing α-tetrahydropyranyl and α-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease. , 2010, Journal of medicinal chemistry.

[24]  J. Baell,et al.  New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. , 2010, Journal of medicinal chemistry.

[25]  Ian Holmes,et al.  The identification of beta-hydroxy carboxylic acids as selective MMP-12 inhibitors. , 2009, Bioorganic & medicinal chemistry letters.

[26]  Woody Sherman,et al.  Novel Method for Generating Structure-Based Pharmacophores Using Energetic Analysis , 2009, J. Chem. Inf. Model..

[27]  K. Umehara,et al.  Matrix metalloproteinase-2 inhibitors from Clinopodium chinense var. parviflorum. , 2009, Journal of natural products.

[28]  W. Cornell,et al.  Discovery of potent, selective, and orally active carboxylic acid based inhibitors of matrix metalloproteinase-13. , 2009, Journal of medicinal chemistry.

[29]  Woody Sherman,et al.  Energetic analysis of fragment docking and application to structure-based pharmacophore hypothesis generation , 2009, J. Comput. Aided Mol. Des..

[30]  C. Luchinat,et al.  Biotin-tagged probes for MMP expression and activation: design, synthesis, and binding properties. , 2009, Bioconjugate chemistry.

[31]  B. Fingleton.  MMPs as therapeutic targets--still a viable option? , 2008, Seminars in cell & developmental biology.

[32]  Y. Okada,et al.  Joint diseases and matrix metalloproteinases: a role for MMP-13. , 2008, Current pharmaceutical biotechnology.

[33]  Robert Huber,et al.  Crystal structures of MMP-9 complexes with five inhibitors: contribution of the flexible Arg424 side-chain to selectivity. , 2007, Journal of molecular biology.

[34]  Jialiang Hu,et al.  Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases , 2007, Nature Reviews Drug Discovery.

[35]  David E. Shaw,et al.  PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results , 2006, J. Comput. Aided Mol. Des..

[36]  C. Dietrich,et al.  Enhanced expression of MMP‐7 and MMP‐13 in inflammatory bowel disease: A precancerous potential? , 2006, Inflammatory bowel diseases.

[37]  Sophie Perrier,et al.  Crystal structures of novel non-peptidic, non-zinc chelating inhibitors bound to MMP-12. , 2004, Journal of molecular biology.

[38]  E. Kaldjian,et al.  Broad-spectrum matrix metalloproteinase inhibitor marimastat-induced musculoskeletal side effects in rats. , 2003, Arthritis and rheumatism.

[39]  G. Fisher,et al.  UV-light-induced signal cascades and skin aging , 2002, Ageing Research Reviews.

[40]  Carlos López-Otín,et al.  Strategies for MMP inhibition in cancer: innovations for the post-trial era , 2002, Nature Reviews Cancer.

[41]  B. Fingleton,et al.  Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations , 2002, Science.

[42]  A. H. Drummond,et al.  Preclinical and Clinical Studies of MMP Inhibitors in Cancer , 1999, Annals of the New York Academy of Sciences.

[43]  H Matter,et al.  Quantitative structure-activity relationship of human neutrophil collagenase (MMP-8) inhibitors using comparative molecular field analysis and X-ray structure analysis. , 1999, Journal of medicinal chemistry.

[44]  S. Parsons,et al.  Dupuytren's disease and frozen shoulder induced by treatment with a matrix metalloproteinase inhibitor. , 1998, The Journal of bone and joint surgery. British volume.

[45]  D. Hupe,et al.  A recombinant human stromelysin catalytic domain identifying tryptophan derivatives as human stromelysin inhibitors. , 1994, Journal of medicinal chemistry.

[46]  Miquel Mulero,et al.  Understanding the variability of the S1' pocket to improve matrix metalloproteinase inhibitor selectivity profiles. , 2019, Drug discovery today.

[47]  Adrià Cereto-Massagué,et al.  Molecular fingerprint similarity search in virtual screening. , 2015, Methods.

[48]  D. Gheonea,et al.  Matrix metalloproteinases (MMP-3 and MMP-9) implication in the pathogenesis of inflammatory bowel disease (IBD). , 2014, Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie.

[49]  F. Gomis-Rüth,et al.  Matrix metalloproteinases: fold and function of their catalytic domains. , 2010, Biochimica et biophysica acta.

[50]  P. Tucker,et al.  Structural insight into the stereoselective inhibition of MMP-8 by enantiomeric sulfonamide phosphonates. , 2006, Journal of medicinal chemistry.

[51]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[52]  John Platt,et al.  Probabilistic Outputs for Support vector Machines and Comparisons to Regularized Likelihood Methods , 1999 .